AbbVie (ABBV) Exercises Option to Acquire TeneoOne

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/12/2026

1. MIRM
2. SPY
3. MSFT
4. META
5. QQQ
6. LDOS
7. PLTR
8. CSCO
9. KTOS
10. NVDA

Go back to AbbVie (ABBV) Exercises Option to Acquire TeneoOne

AbbVie Exercises Right to Acquire TeneoOne and Lead Asset TNB-383B for the Potential Treatment of Relapsed or Refractory Multiple Myeloma

June 24, 2021 8:00 AM EDT

NORTH CHICAGO, Ill. and NEWARK, Calif., June 24, 2021 /PRNewswire/ -- AbbVie (NYSE: ABBV) and Teneobio, Inc. announced today that AbbVie exercised its exclusive right to acquire TeneoOne, an affiliate of Teneobio, Inc., and TNB-383B, a BCMA-targeting immunotherapeutic for the potential treatment of relapsed or refractory multiple myeloma (R/R MM). In February 2019, AbbVie and TeneoOne entered a strategic transaction to develop and commercialize TNB-383B, a bispecific antibody that simultaneously targets BCMA and CD3 and is designed to direct the body's own immune system to target and kill BCMA-expressing tumor... More